Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Targets |
Endogenous Metabolite
|
---|---|
ln Vitro |
Co-treating LPS (1 μg/mL) with ATP (5 mM) for one hour has a positive impact on HGFs' NLRP3 inflammasome activation [3]. IL-1β, KC, and MIP-2 are all required for the caspase-1 activation-dependent induction of BMDM mortality by ATP (2 mM; 0.5-24 hours) [4]. In vitro, ATP stimulates neutrophil chemotaxis [4].
|
ln Vivo |
ATP (50 mg/kg; ip) protects the outer shell against infecting bacteria [4]. ATP covers IL-1β, KC and MIP-2 in the periphery as well as neutrophil recruitment [4].
|
Enzyme Assay |
Human health is under constant threat of a wide variety of dangers, both self and nonself. The immune system is occupied with protecting the host against such dangers in order to preserve human health. For that purpose, the immune system is equipped with a diverse array of both cellular and non-cellular effectors that are in continuous communication with each other. The naturally occurring nucleotide adenosine 5'-triphosphate (ATP) and its metabolite adenosine (Ado) probably constitute an intrinsic part of this extensive immunological network through purinergic signaling by their cognate receptors, which are widely expressed throughout the body. This review provides a thorough overview of the effects of ATP and Ado on major immune cell types. The overwhelming evidence indicates that ATP and Ado are important endogenous signaling molecules in immunity and inflammation. Although the role of ATP and Ado during the course of inflammatory and immune responses in vivo appears to be extremely complex, we propose that their immunological role is both interdependent and multifaceted, meaning that the nature of their effects may shift from immunostimulatory to immunoregulatory or vice versa depending on extracellular concentrations as well as on expression patterns of purinergic receptors and ecto-enzymes. Purinergic signaling thus contributes to the fine-tuning of inflammatory and immune responses in such a way that the danger to the host is eliminated efficiently with minimal damage to healthy tissues[2].
|
Cell Assay |
In vitro studies suggest that extracellular nucleotides and nucleosides may be important regulators of inflammatory and immune responses. Most studies with adenosine 5'-triphosphate (ATP) have been performed in cell lines, which are remote from the human situation. The purpose of the present study was to determine the effects of ATP on TNF-alpha, IL-6 and IL-10 release in stimulated whole blood. Blood samples were drawn from healthy volunteers and incubated with ATP and lipopolysaccharide (LPS) + phytohemagglutinin (PHA) for 24 h. Contrary to expectations, ATP at 100 microM and 300 microM induced a reduction in TNF-alpha secretion by 32+/-8% (mean +/- SEM) and 65+/-4%, respectively. Furthermore, these ATP concentrations induced an increase in IL-10 secretion by 48+/-5% and 62+/-7% in whole blood. The ATP analogue adenosine 5'-O-(3-thiotriphosphate) (ATP-gamma-S) and adenosine 5'-diphosphate (ADP) also inhibited TNF-alpha release, but only ADP showed a stimulatory effect on IL-10. Co-treatment with adenosine deaminase did not reverse the ATP effect on TNF-alpha and IL-10. These results show, for the first time, that ATP inhibits the inflammatory response in stimulated whole blood as indicated by inhibition of TNF-alpha and stimulation of IL-10 release and that this effect is predominantly mediated by ATP and not by adenosine[1].
|
Animal Protocol |
Animal/Disease Models: Fourweeks old Kunming mice (18-22 g) [4]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection before bacterial (E. coli) challenge Experimental Results: Protect mice from bacterial infection. |
ADME/Pharmacokinetics |
Metabolism / Metabolites
Metabolism of organophosphates occurs principally by oxidation, by hydrolysis via esterases and by reaction with glutathione. Demethylation and glucuronidation may also occur. Oxidation of organophosphorus pesticides may result in moderately toxic products. In general, phosphorothioates are not directly toxic but require oxidative metabolism to the proximal toxin. The glutathione transferase reactions produce products that are, in most cases, of low toxicity. Paraoxonase (PON1) is a key enzyme in the metabolism of organophosphates. PON1 can inactivate some organophosphates through hydrolysis. PON1 hydrolyzes the active metabolites in several organophosphates insecticides as well as, nerve agents such as soman, sarin, and VX. The presence of PON1 polymorphisms causes there to be different enzyme levels and catalytic efficiency of this esterase, which in turn suggests that different individuals may be more susceptible to the toxic effect of organophosphate exposure. |
Toxicity/Toxicokinetics |
Toxicity Summary
ATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. ATP can be produced by various cellular processes, most typically in mitochondria by oxidative phosphorylation under the catalytic influence of ATP synthase. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis. Toxicity Data Oral LD50 in rats is > 2 g/kg. |
References |
|
Additional Infomation |
ATP is an adenosine 5'-phosphate in which the 5'-phosphate is a triphosphate group. It is involved in the transportation of chemical energy during metabolic pathways. It has a role as a nutraceutical, a micronutrient, a fundamental metabolite and a cofactor. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-triphosphate. It is a conjugate acid of an ATP(3-).
Adenosine triphosphate is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Adenosine-5'-triphosphate has been reported in Helianthus tuberosus, Arabidopsis thaliana, and other organisms with data available. Adenosine Triphosphate is an adenine nucleotide comprised of three phosphate groups esterified to the sugar moiety, found in all living cells. Adenosine triphosphate is involved in energy production for metabolic processes and RNA synthesis. In addition, this substance acts as a neurotransmitter. In cancer studies, adenosine triphosphate is synthesized to examine its use to decrease weight loss and improve muscle strength. Adenosine triphosphate (ATP) is a nucleotide consisting of a purine base (adenine) attached to the first carbon atom of ribose (a pentose sugar). Three phosphate groups are esterified at the fifth carbon atom of the ribose. ATP is incorporated into nucleic acids by polymerases in the processes of DNA replication and transcription. ATP contributes to cellular energy charge and participates in overall energy balance, maintaining cellular homeostasis. ATP can act as an extracellular signaling molecule via interactions with specific purinergic receptors to mediate a wide variety of processes as diverse as neurotransmission, inflammation, apoptosis, and bone remodelling. Extracellular ATP and its metabolite adenosine have also been shown to exert a variety of effects on nearly every cell type in human skin, and ATP seems to play a direct role in triggering skin inflammatory, regenerative, and fibrotic responses to mechanical injury, an indirect role in melanocyte proliferation and apoptosis, and a complex role in Langerhans cell-directed adaptive immunity. During exercise, intracellular homeostasis depends on the matching of adenosine triphosphate (ATP) supply and ATP demand. Metabolites play a useful role in communicating the extent of ATP demand to the metabolic supply pathways. Effects as different as proliferation or differentiation, chemotaxis, release of cytokines or lysosomal constituents, and generation of reactive oxygen or nitrogen species are elicited upon stimulation of blood cells with extracellular ATP. The increased concentration of adenosine triphosphate (ATP) in erythrocytes from patients with chronic renal failure (CRF) has been observed in many studies but the mechanism leading to these abnormalities still is controversial. (A3367, A3368, A3369, A3370, A3371). Adenosine triphosphate is a metabolite found in or produced by Saccharomyces cerevisiae. An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. |
Molecular Formula |
C10H16N5O13P3
|
---|---|
Molecular Weight |
507.1810
|
Exact Mass |
506.995
|
Elemental Analysis |
C, 23.68; H, 3.18; N, 13.81; O, 41.01; P, 18.32
|
CAS # |
56-65-5
|
Related CAS # |
ATP disodium salt;987-65-5;ATP disodium trihydrate;51963-61-2;ATP dimagnesium;74804-12-9;ATP-13C10,15N5 disodium;ATP disodium salt hydrate;34369-07-8;ATP dipotassium;42373-41-1;ATP ditromethamine;102047-34-7;ATP-13C10,15N5;752972-20-6
|
PubChem CID |
5957
|
Appearance |
White to off-white solid powder
|
Density |
2.6±0.1 g/cm3
|
Boiling Point |
951.4±75.0 °C at 760 mmHg
|
Melting Point |
187 - 190ºC (Decomposes)
|
Flash Point |
529.2±37.1 °C
|
Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
Index of Refraction |
1.904
|
LogP |
-4.18
|
Hydrogen Bond Donor Count |
7
|
Hydrogen Bond Acceptor Count |
17
|
Rotatable Bond Count |
8
|
Heavy Atom Count |
31
|
Complexity |
800
|
Defined Atom Stereocenter Count |
4
|
SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
|
InChi Key |
ZKHQWZAMYRWXGA-KQYNXXCUSA-N
|
InChi Code |
InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
Chemical Name |
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
|
Synonyms |
Adenosine triphosphate; Ara-ATP; Atipi; Triphosphaden; Triphosphoric acid adenosine ester; Adenosine 5'-triphosphate; ATP; adenosine-5'-triphosphate; Myotriphos; Striadyne; Triadenyl;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~197.17 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (197.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9717 mL | 9.8584 mL | 19.7169 mL | |
5 mM | 0.3943 mL | 1.9717 mL | 3.9434 mL | |
10 mM | 0.1972 mL | 0.9858 mL | 1.9717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02580253 | Withdrawn | Drug: Individualized Chemotherapy Drug: mFOLFOX6 |
Hepatocellular Carcinoma | Zhejiang University | November 1, 2017 | Phase 2 |
NCT00014248 | Completed | Drug: adenosine triphosphate Procedure: quality-of-life assessment |
Cachexia Unspecified Adult Solid Tumor, Protocol Specific |
Dartmouth-Hitchcock Medical Center | October 2000 | Phase 1 |
NCT00565188 | Completed | Drug: Adenosine 5'-triphosphate | Cancer Palliative Care |
Maastricht University Medical Center | March 2002 | Phase 3 |
NCT02279511 | Completed | Drug: ADENOSINE TRIPHOSPHATE Drug: PLACEBO |
Alzheimer's Disease | Sara Varea | December 2014 | Phase 2 |